Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion. OBJECTIVE: The objective of the study was to determine whether exenatide can restore a more normal pattern of insulin secretion in subjects with DM2. DESIGN: Fasted subjects received iv insulin infusion to reach plasma glucose 4.4-5.6 mmol/liter. Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge. PATIENTS: Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2). Controls included 12 healthy, weight-matched subjects with normal glucose tolerance: nine males, three females; age, 57 +/- 9 yr; and body mass index, 32.0 +/- 3.0 kg/m2. SETTING: The study was conducted at an academic hospital. MAIN OUTCOME MEASURES: Plasma insulin, plasma C-peptide, insulin secretion rate (derived by deconvolution), and plasma glucagon were the main outcome measures. RESULTS: DM2 subjects administered saline had diminished first-phase insulin secretion, compared with healthy control subjects. Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects. In exenatide-treated DM2 subjects, the most common adverse event was moderate nausea (two of 13 subjects). CONCLUSIONS: Short-term exposure to exenatide can restore the insulin secretory pattern in response to acute rises in glucose concentrations in DM2 patients who, in the absence of exenatide, do not display a first phase of insulin secretion. Loss of first-phase insulin secretion in DM2 patients may be restored by treatment with exenatide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [71]
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 2×
“Diabetes duration (yr) 4 2 NA Diabetes treatment [n (%)] -Glucosidase inhibitors 2 (15) NA Metformin 10 (77) NA Diet/exercise 1 (7) NA”
BackgroundSelf-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“Insulin, Cpeptide, and glucagon were determined by specific immunoassays as previously described (28, 29).”
MethodSelf-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“glucose in patients with T2DM, hence improving the ability of cells to response to rapid glycemic changes (Fehse et al., 2005).”
BackgroundPancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
“This effect is consistent with the ability of exenatide to improve -cell function acutely (83).”
ResultMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
“60 min after the start of the clamp at an infusion rate of 50 ng/min for 30 min and was decreased to 25 ng/min for the remaining time of the clamp procedure (22).”
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
“The slow increase (compared with a primed infusion) probably explains why the infusion did not augment firstphase insulin secretion (0–10 min) in the healthy controls, as observed in other studies [32], and also did not result in any early stimulation of insulin secretion in the patients either before or after insulin…”
ResultSelf-citationBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
“A sample size of 26 patients per group was required to provide 90% power to detect a betweengroup significant difference in argininestimulated insulin secretion between the two treatment groups, assuming that the mean incremental AUC value at baseline is 200 pmol min 1 l 1 for both groups and values at week 52 are 1,1…”
Dynamics of insulin secretion and the clinical implications for obesity and diabetes
Seino, S., Shibasaki, T., & Minami, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45680 · Cited by 364
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Self-citationElkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
“Among the primary actions of EX in subjects with DM2 is the ability to restore first- and second-phase I secretion, which is attenuated in this population ( 18 ).”
BackgroundMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“In early studies in type 2 diabetes, exenatide demonstrated the ability of GLP-1 RA to enhance β cell secretory function, effectively restoring defective first-phase insulin response and significantly increasing the second-phase insulin response to intravenous glucose.(6) Longer term studies have confirmed the sustain…”
BackgroundRole of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
Meier, J. J., & Bonadonna, R. C. (2013) · Diabetes Care · doi:10.2337/dcs13-2008 · Cited by 242
“That glucoseinduced insulin secretion can be almost fully normalized even within ,1 day sheds doubts on the idea of a primary functional b-cell abnormality in type 2 diabetes (23,24).”
Backgroundβ-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
“term treatments with DPP-4 inhibitors (70) and GLP-1 receptor agonists (71, 72) However, while augmented insulin production as assessed with glucose- and arginine-stimulation continues during active treatment and is of clinical value, none of these agents has produced a meaningful, persistent change following therapy…”
BackgroundIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217
Self-citationVilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
“An early effect on B-cell function was previously demonstrated with both liraglutide and exenatide [13,14, 19 ,20].”
BackgroundDiabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
“Through binding on specific receptors on beta cells and increases of intracellular cyclic AMP (cAMP) and calcium, incretins stimulate the GSIS, improving both first- and second-phase responses and restoring the biphasic profile (60,62,63).”
BackgroundVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Self-citationKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
“However, measures of β-cell function (homeostasis model assessment [HOMA]–B and HOMA-IR) are improved in the setting of both exenatide and liraglutide treatment [61,93-97].”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
“This rate of exenatide infusion was shown to provide a rapid and stable concentration similar to peak concentrations after typical subcutaneous exenatide injections (30).”
BackgroundMethodNavarro, G., Xu, W., Jacobson, D. A., Wicksteed, B., Allard, C., Zhang, G., De Gendt, K., Kim, S. H., Wu, H., Zhang, H., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.015 · Cited by 171
“Recently, an observational study from the Veterans Healthcare Administration showed that among prostate cancer patients, androgen deprivation therapy with GnRH agonists was associated with an increased risk for T2D (Keating et al., 2012).”
InfluentialFunctional Assessment of Pancreatic β-Cell Area in Humans
Meier, J. J., Menge, B. A., Breuer, T. G. K., Müller, C. A., Tannapfel, A., Uhl, W., Schmidt, W. E., & Schrader, H. (2009) · Diabetes · doi:10.2337/db08-1611 · Cited by 163
“Furthermore, the insulin responses to intravenous glucose administration in patients with type 2 diabetes can be enhanced acutely by 300% after the infusion of a GLP-1 analogue over 5 h (31), a time period during which any gain in -cell mass is far from being realistic.”
BackgroundJakubowicz, D. J., Froy, O., Åhrén, B., Boaz, M., Landau, Z., Bar‐Dayan, Y., Ganz, T., Barnea, M., & Wainstein, J. (2014) · Diabetologia · doi:10.1007/s00125-014-3305-x · Cited by 158
“Another approach is to target the incretin hormone glucagon-like peptide-1 (GLP-1), which is an important mediator for the postprandial insulin response [3].”
BackgroundBeta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155
“Furthermore, glucose-induced insulin secretion is subject to considerable day to day variation, and can be modulated to a large extent by pharmacological interventions, such as an overnight infusion of a GLP-1 analogue [73], temporary inhibition of insulin secretion [74] or prolonged glucose normalisation by the admin…”
BackgroundBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 142
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“Additionally, the first phase of insulin secretion, which is already lost in the early stages of type 2 diabetes, is restored under treatment with exenatide when examined with an intravenous glucose tolerance test.([28,44,49]) Whether the improvements of these b-cell function parameters are sustained over year-long tr…”
Bose, M., Oliván, B., Teixeira, J., Pi-Sunyer, F. X., & Laferrère, B. (2009) · Obesity Surgery · doi:10.1007/s11695-008-9696-3 · Cited by 128
“Infusion of the GLP-1 or a GLP-1 analog increased first-phase insulin secretion in patients with T2DM [99] and in normoglycemic subjects [100]; the increase of Bose et al.”
BackgroundMadsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 134
Insulin granule biogenesis and exocytosis
Omar-Hmeadi, M., & Idevall-Hagren, O. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03688-4 · Cited by 126
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
“This schedule has been previously shown to yield plasma exenatide levels within the therapeutic range (130–150 pg/ml), with identical pharmacokinetics as observed after subcutaneous injection, and is well tolerated [12, 13].”
Grieve, D. J., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121
“These studies have reported that type 2 diabetic patients chronically treated with Byetta demonstrate marked increases in first- and second-phase insulin secretion, suppression of postprandial glucagon secretion, significant reductions in postprandial hyperglycaemia and improved basal glycaemic control (Kolterman et a…”
BackgroundBarrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
“Exenatide has been shown to restore first-phase insulin response [2], improve glycaemic control and promote weight loss in diabetic patients [3].”
BackgroundThe effects of glucagon‐like peptide‐1 on the beta cell
Vilsbøll, T. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01073.x · Cited by 115
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
“Like GLP-1, exenatide slows gastric emptying [60], suppresses glucagon [61, 62] and enhances first- and second-phase glucose-stimulated insulin secretion, as well as insulin secretion in response to a combined glucose and arginine stimulus [63–65].”
BackgroundSelf-citationSnapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion
Song, W.-J., Seshadri, M., Ashraf, U., Mdluli, T., Mondal, P., Keil, M., Azevedo, M., Kirschner, L. S., Stratakis, C. A., & Hussain, M. A. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.002 · Cited by 114
“These results provide a basis for functional impairment in insulin secretion in DIO diabetic islets, which, consistent with clinical observations, can acutely be reversed with E4-mediated incretin action (Egan et al., 2002; Fehse et al., 2005).”
BackgroundResultTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110
“receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.”
BackgroundTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111
“Exenatide improves insulin secretion in subjects with T2DM who previously did not display a normal first-phase response [57].”
BackgroundExenatide: a review from pharmacology to clinical practice
Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 111
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Jalil, A. M. M., Ismail, A., Chong, P. P., Hamid, M., & Kamaruddin, S. H. S. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8015915 · Cited by 107
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Ren, J., Jin, P., Wang, E., Liu, E., Harlan, D. M., Li, X., & Stroncek, D. F. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-1 · Cited by 114
Cvetkovi, R. S., & Plosker, G. L. (2007) · Drugs · doi:10.2165/00003495-200767060-00008 · Cited by 117
Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0985-7 · Cited by 102
“Exenatide (EXE) is the synthetic analog of exendin-4, a GLP-1 homologous originally purified from the salivary glands of the lizard Heloderma suspectum, and it is currently employed in the treatment of type 2 diabetes (T2D) [3, 4].”
InfluentialMuskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102
“As we aimed for stable pharmacological GLP-1 receptor agonist concentrations with our validated infusion protocol [18], the exenatide-induced renal haemodynamic alterations observed in the present study could be attributable to higher plasma concentrations, reflecting a clinically more relevant condition.”
BackgroundThe RISE Consortium (2014) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 100
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other incretinbased therapies also improve islet function (13,14), likely by augmenting b-cell insulin release and suppressing a-cell glucagon secretion.”
BackgroundFaradji, R. N., Tharavanij, T., Messinger, S., Froud, T., Pileggi, A., Monroy, K., Mineo, D., Baidal, D. A., Cure, P., Ponte, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31818fe448 · Cited by 97
“These show improved -cell secretory capacity similar to that observed after EXN administration in patients with type 2 diabetes (26,27).”
BackgroundDavis, S. N., Johns, D., Maggs, D. G., Xu, H., Northrup, J., & Brodows, R. G. (2007) · Diabetes Care · doi:10.2337/dc06-2532 · Cited by 99
Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 93
Self-citationIncretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
“EFFECT OF GLP-1 AGONISTS ON b-CELL MASS AND FUNCTION—Although native GLP-1 is rapidly degraded by the enzyme DPP-4 in the plasma, limiting its therapeutic potential because of its short half-life (,2 min), the beneficial properties of GLP-1 have been harnessed with the development of the longer-acting GLP-1 receptor a…”
BackgroundExenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus
Iltz, J. L., Baker, D. E., Setter, S. M., & Campbell, R. K. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.006 · Cited by 103
Wu, J.-D., Xu, X.-H., Zhu, J., Ding, B., Du, T.-X., Gao, G., Mao, X.-M., Ye, L., Lee, K.-O., & Ma, J.-H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0048 · Cited by 89
Sheffield, C. A., Kane, M. P., Busch, R., Bakst, G., Abelseth, J. M., & Hamilton, R. A. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.285 · Cited by 87
Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., et al. (2016) · Diabetes · doi:10.2337/db15-0893 · Cited by 83
“5 mg) was within the usual clinical range and was infused in a regimen shown previously to achieve steady therapeutic plasma concentrations (14,15).”
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Kaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B. (2013) · Diabetes · doi:10.2337/db12-1013 · Cited by 80
“The most promising therapies to restore biphasic insulin release are the incretin hormone–based therapies (34).”
BackgroundBarnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 83
Self-citationMartinussen, C., Bojsen-Møller, K. N., Dirksen, C., Jacobsen, S. H., Jørgensen, N. B., Kristiansen, V. B., Holst, J. J., & Madsbad, S. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00506.2014 · Cited by 74
“It could be argued that the increased postprandial GLP-1 levels during the days preceding the IVGTT could in part explain the enhanced first-phaseISR and AIRg after RYGB, since pharmacological administration of GLP-1 or GLP-1 agonists have been shown to restore both first- and second-phase insulin secretion to iv gluc…”
Self-citationEmerging Epidemic: Diabetes in Older Adults: Demography, Economic Impact, and Pathophysiology
Gambert, S. R., & Pinkstaff, S. M. (2006) · Diabetes Spectrum · doi:10.2337/diaspect.19.4.221 · Cited by 87
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
InfluentialLiraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126003 · Cited by 70
“Exenatide was reported to normalize both first and second phases of glucose-induced insulin secretion in patients with type 2 diabetes during 3-hour intravenous infusion [10] and to provide long-term improvement of beta cell function by chronic treatment [11].”
Backgroundvan Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Drent, M. L., Barkhof, F., Diamant, M., & IJzerman, R. G. (2015) · Obesity · doi:10.1002/oby.21200 · Cited by 67
“Intravenous exenatide (Byetta; Eli Lilly) or placebo infusion was started 60 minutes after the start of the clamp at an infusion rate of 50 ng/min for 30 minutes, and was decreased to 25 ng/min for the remaining time of the clamp procedure (16).”
MethodKhedkar, A., Iyer, H., Anand, A. C., Verma, M., Krishnamurthy, S., Savale, S. S., & Atignal, A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01213.x · Cited by 69
“Unlike other hypoglycaemic agents that stimulate the early phase insulin rise [9,10], IN-105 does not deplete the pancreatic pool, as is apparent from the accompanying reduced endogenous C-peptide levels [2].”
BackgroundCardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 72
Nakatsu, D., Horiuchi, Y., Kano, F., Noguchi, Y., Sugawara, T., Takamoto, I., Kubota, N., Kadowaki, T., & Murata, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417197112 · Cited by 77
“The first phase involves a sharp increase in insulin secretion within ∼5 min, followed by a second phase, during which moderate insulin secretion lasts for hours (9, 12).”
BackgroundMudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
Ranganath, L. R. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043232 · Cited by 66
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“[67] recently demonstrated the ability of intravenous exenatide to restore first phase insulin secretion in response to intravenous glucose in patients with Type 2 diabetes.”
BackgroundGALLWITZ, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
Dalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12843 · Cited by 60
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
Exenatide: From the Gila Monster to the Pharmacy
Triplitt, C. L., & Chiquette, E. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506775268698 · Cited by 69
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Self-citationAn examination of β‐cell function measures and their potential use for estimating β‐cell mass
Kahn, S. E., Carr, D. B., Faulenbach, M. V., & Utzschneider, K. M. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00945.x · Cited by 60
The entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 72
Gaal, L. F. V., Gutkin, S. W., & Nauck, M. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0804 · Cited by 66
Self-citationMcCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-013-0172-6 · Cited by 65
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Self-citationSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0507 · Cited by 54
Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
Tudurí, E., López, M., Diéguez, C., Nadal, Á., & Nogueiras, R. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.004 · Cited by 56
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 49
Función endocrina en la obesidad
Álvarez-Castro, P., Sangiao‐Alvarellos, S., Brandón-Sandá, I., & Cordido, F. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.05.015 · Cited by 79
Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
Hinnen, D., Nielsen, L. L., Waninger, A., & Kushner, P. (2006) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.19.6.612 · Cited by 63
Self-citationDiabetes mellitus and gastric emptying: questions and issues in clinical practice
Samsom, M., Bharucha, A., Gerich, J. E., Herrmann, K., Limmer, J., Linke, R., Maggs, D., Schirra, J., Vella, A., Wörle, H., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.974 · Cited by 48
“In long-term studies of patients with T2DM, exenatide restored first-phase insulin secretion [152], significantly improved HbA1c levels, reduced postprandial hyperglycaemia, and lowered body weight [122–124].”
BackgroundEffects of exendin‐4 on islets from type 2 diabetes patients
Lupi, R., Mancarella, R., Del Guerra, S., Bugliani, M., Del Prato, S., Boggi, U., Mosca, F., Filipponi, F., & Marchetti, P. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00838.x · Cited by 47
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P., Bailey, C., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 44
Metadata
- Authors
- Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Eli Lilly (United States) (US)
- University of Copenhagen (DK)
- Corresponding author
- Nauck, Michael A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-11
- Volume
- 90
- Issue
- 11
- Pages
- 5991-5997
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2039296612
- Cited by
- 297
- References
- 55
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 24 · 2014: 22 · 2013: 21 · 2012: 9
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, incretin mimetics, glucose-dependent insulin secretion, insulin secretion rate, C-peptide, glucagon, insulin resistance, metformin, acarbose, glucoregulation, GLP-1 receptor
- MeSH terms
- Exenatide, Insulin Secretion, Adult, Diabetes Mellitus, Type 2, Female, Glucose, Humans, Insulin, Male, Middle Aged, Peptides, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.